Henry W. Green

Learn More
OBJECTIVE To evaluate antiplatelet effects and pharmacodynamics of clopidogrel in cats. DESIGN Original study. ANIMALS 5 purpose-bred domestic cats. PROCEDURE Clopidogrel was administered at dosages of 75 mg, p.o., every 24 hours for 10 days; 37.5 mg, p.o., every 24 hours for 10 days; and 18.75 mg, p.o., every 24 hours for 7 days. In all cats,(More)
OBJECTIVE To determine whether ticlopidine exerts an antiplatelet effect, estimate the pharmacodynamics of ticlopidine, and evaluate any acute adverse effects associated with administration of ticlopidine in cats. ANIMALS 8 domestic purpose-bred sexually intact male cats. PROCEDURE Ticlopidine was administered orally (50 mg, q 24 h; 100 mg, q 24 h; 200(More)
Patent ductus arteriosus (PDA) is the most common congenital cardiac disease in the dog and generally leads to severe clinical signs, including left-sided congestive heart failure. Historically, definitive treatment consisted of surgical ligation; however, the use of vascular occlusion devices by minimally invasive techniques has gained popularity in(More)
Superior vena caval syndrome is a rare, but reported complication of transvenous pacemaker implantation in humans. This syndrome can occur secondary to fibrotic and/or thrombotic obstruction of venous blood flow into the right atrium. The therapeutic approach depends on the suspicion of the presence of an active thrombus and may include antithrombotics,(More)
Skeletal muscle atrophy results from an imbalance in protein degradation and protein synthesis and occurs in response to injury, various disease states, disuse, and normal aging. Current treatments for this debilitating condition are inadequate. More information about mechanisms involved in the onset and progression of muscle atrophy is necessary for(More)
A 4-month-old, intact female mixed-breed dog presented to the Purdue University Veterinary Teaching Hospital for evaluation of a cardiac murmur. A large left-to-right patent ductus arteriosus (PDA) was diagnosed and interventional correction was achieved with a commercially available peripheral vascular occlusion device (VOD). The VOD is composed of a(More)
OBJECTIVE To establish practical doses and administration frequencies of fondaparinux for cats that would approximate human therapeutic peak and trough plasma anti-factor Xa activities for thromboprophylaxis (TP) and thrombosis treatment (TT) protocols. ANIMALS 6 healthy adult purpose-bred cats. PROCEDURES Dosage protocols for TP and TT were selected on(More)
BACKGROUND Congential extrahepatic portosystemic shunts (EHPSS) are common in dogs. An effective minimally invasive technique for correction of EHPSS could result in reduced morbidity, reduced costs, and reduced hospitalization times. HYPOTHESIS Use of an intravascular occlusion device can effectively and safely result in acute complete occlusion of EHPSS(More)